Skip to main content
OpenTrials
Completed

NCT Number: NCT06163053

A Study to Evaluate Satisfaction With Care in Patients With Cancer Receiving Immunotherapy Treatment at Home

The purpose of this observational study in France is to evaluate changes in satisfaction with care in participants with solid tumors who transitioned from receiving immunotherapy treatment in the hospital outpatient setting to receiving treatment at home

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Neoplasms Solid Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CH Metropole Savoie, Chambéry, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female ≥ 18 years old
  • Participants whose oncology specialist has already initiated treatment with immune checkpoint inhibitors (ICIs) in the outpatient hospital setting for an advanced solid tumor (as monotherapy or in combination) or as adjuvant therapy, in an indication approved and reimbursed in France
  • Participants whose oncology specialist has independently of the study defined their eligibility for hospital at home (HAH) before contacting the HAH unit for final admission
  • Participants who provide oral informed consent to participate in the study

Exclusion criteria

  • Participants who have expressed an opposition to their data collection
  • Participants under guardianship
  • Participants taking part in an interventional study for cancer treatment with at least one ICI as an investigational drug

Treatment and study plan

Immunotherapy

Drug

Immune checkpoint inhibitors in approved indications

Primary outcomes

  1. Change in patient satisfaction on the European Organisation for Research and Treatment of Cancer satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) when transitioning from Outpatient Hospital to Hospital at Home to receive immunotherapy

    Time frame: Participants follow up approximately 24 weeks after transition to treatment at home

Sponsors and collaborators

Lead sponsor

Bristol-Myers Squibb

Industry

Registry information

Official study title

A French Non-interventional Prospective Multicenter Study Evaluating Quality of Care Perception of Cancer Patients Treated by Immunotherapy at Home - SATISFACT-HOME

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Dec 8, 2023
Registry last updated
Jan 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.